摘要
目的探讨米托蒽醌联合阿糖胞苷(MA方案)作为成人初治急性髓细胞性白血病(AML)一线诱导化疗方案的可行性。方法回顾性对照分析MA方案和柔红霉素或三尖杉酯碱联合阿糖胞苷(DA/HA方案)诱导治疗成人初治AML的疗效及不良反应。结果MA方案组与DA/HA方案组完全缓解率分别是52.5%和30.4%(P=0.09)。两组方案诱导期死亡率分别是7.5%和8.7%(P>0.05)。MA方案对WBC的抑制作用重于DA/HA方案(P<0.05),但对Hb、PLT的抑制程度以及不良反应方面,两组方案无显著性差异。结论MA方案诱导治疗成人初治AML的完全缓解率高于DA/HA方案,两组方案不良反应无显著性差异,MA方案可以作为成人初治AML患者一线诱导化疗方案之一。
Objective To explore the feasibility of mitoxantrone （MTZ） plus cytarabine （Ara-C） （MA regimen） as the first line therapy in the induction treatment of previously untreated patients with acute myeloid leukemia （AML）. Methods Retrospective studying the efficacy and toxicity of previously untreated patients with AML who treated with MA regimen and daunorubicin （DNR） or harringtonine （HT） plus Ara-C （DA/HA regimen）. Results In MA regimen and DA/HA regimen, the complete remission （CR） rates were 52.5% and 30.4%（P=0. 090） , respectively. The death rates in the induction therapy period were 7.5% and 8.7% （P〉0.05）, respectively. In MA regimen WBC depression was more serious than that in DA/HA regimen （P〈0.05）, but no significant differences were found in Hb, PLT depression or the incidence and severity of side effects （P〉0.05）. Conclusion The complete remission （CR） rate is higher in MA regimen than that in DA/HA regimen, but no significant differences are found in side effects between two regimens. MA regimen is recommended as one of the first line therapy in the induction treatment of previously untreated patients with AML.
出处
《重庆医学》
CAS
CSCD
2005年第9期1301-1303,共3页
Chongqing medicine
